Business Context and Reporting Period
Company: Myriad Genetics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2005
Overview: Myriad is a biotechnology company focused on developing therapeutic and molecular diagnostic products. The company operates three segments: research, predictive medicine, and drug development. While the predictive medicine segment is profitable, the company has not yet attained overall profitability due to significant investments in drug discovery and clinical trials.
Key Financial Metrics
| Metric (in thousands) | Fiscal 2005 | Fiscal 2004 |
|---|---|---|
| Total Revenues | $82,406 | $56,648 |
| Predictive Medicine Revenue | $71,325 | $43,294 |
| Research Revenue | $11,081 | $13,354 |
| Net Loss | $(39,978) | $(40,620) |
| Operating Loss | $(40,745) | $(42,635) |
| Research & Development Expense | $59,243 | $50,697 |
| Cash, Cash Equivalents & Marketable Securities | $113,843 | $141,839 |
| Accumulated Deficit | $(179,249) | $(139,271) |
| Working Capital | $112,270 | $148,586 |
Margins: The predictive medicine segment achieved a gross profit margin of 72% in 2005, up from 68% in 2004. The company reported a net loss per share of $1.30 for 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 45% to $82.4 million, driven primarily by a 65% surge in predictive medicine revenue ($71.3 million) due to increased sales and marketing efforts.
- Research Revenue Decline: Research revenue decreased 17% to $11.1 million, attributed to the completion of two major research collaborations.
- Expense Increases: R&D expenses rose 17% to $59.2 million due to ongoing clinical trials for Alzheimer's and cancer. Selling, general, and administrative (SG&A) expenses increased 25% to $43.6 million to support the growth of the predictive medicine business.
- Liquidity: Cash and marketable securities decreased by $28.0 million (20%) to $113.8 million, primarily due to capital expenditures and increased clinical trial costs.
- Impairment Charge: The company recorded a $2.0 million impairment charge related to an investment in a privately-held pharmaceutical company.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Profitability: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and facility expansion.
- Liquidity: The company believes existing capital resources ($113.8 million) are sufficient to fund operations for at least the next two years.
- Capital Raising: Myriad has an effective shelf registration for up to $300 million of securities and intends to raise funds when market conditions are favorable.
Key Clinical Developments
- Flurizan (Alzheimer's): Phase 2 results showed a 34-45% slowing of decline in mild Alzheimer's patients. A Phase 3 study enrolling 1,600 patients has been initiated.
- Flurizan (Prostate Cancer): A Phase 2/3 trial is underway to assess the drug's ability to delay metastatic disease.
- MPC-6827 & MPC-2130: Both candidates are in Phase 1 clinical trials for solid tumors, brain metastasis, and blood cancers.
Risks and Contingencies
- Regulatory Approval: No therapeutic products have received FDA approval. Success in early trials does not guarantee approval, and clinical trials are subject to delays and failures.
- Intellectual Property: The company relies on 234 issued patents and numerous applications. Risks include patent challenges, infringement claims, and the inability to protect trade secrets.
- Reimbursement: Future revenue depends on third-party payors (insurance, Medicare) providing adequate reimbursement for predictive medicine and future therapeutic products.
- Stock Volatility: The stock price is highly volatile and subject to market fluctuations unrelated to operating performance.
Investor Verification Checklist
- Cash Runway: Verify if the $113.8 million cash balance remains sufficient given the high burn rate of clinical trials (R&D expenses of $59.2M vs. total revenue of $82.4M).
- Flurizan Phase 3 Enrollment: Monitor the progress and patient enrollment rates of the pivotal Phase 3 Alzheimer's trial, which is critical for future revenue.
- Predictive Medicine Margins: Confirm if the 72% gross margin in the predictive medicine segment is sustainable as volume increases.
- Research Collaboration Pipeline: Assess the pipeline for new research collaborations to replace the revenue lost from completed agreements.
- Regulatory Status: Track FDA communications regarding the Phase 3 Alzheimer's trial and the Phase 2/3 prostate cancer trial.